iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 1-Year High – Here’s Why

Posted by Jeff Wilder on Jun 13th, 2026

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) shares hit a new 52-week high on Thursday . The stock traded as high as $94.89 and last traded at $93.34, with a volume of 47710 shares. The stock had previously closed at $93.79.

iShares U.S. Pharmaceuticals ETF Trading Down 0.3%

The firm has a fifty day moving average of $89.08 and a two-hundred day moving average of $87.51. The company has a market cap of $1.02 billion, a PE ratio of 17.75 and a beta of 0.50.

Institutional Investors Weigh In On iShares U.S. Pharmaceuticals ETF

Several large investors have recently added to or reduced their stakes in IHE. Foundations Investment Advisors LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF in the 4th quarter worth about $54,513,000. BNP Paribas Financial Markets purchased a new stake in iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth about $13,108,000. Anfield Capital Management LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF in the 4th quarter worth about $10,007,000. JPMorgan Chase & Co. grew its holdings in iShares U.S. Pharmaceuticals ETF by 89.4% during the 4th quarter. JPMorgan Chase & Co. now owns 212,805 shares of the company’s stock valued at $18,052,000 after buying an additional 100,426 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in iShares U.S. Pharmaceuticals ETF by 675.4% during the 1st quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock valued at $9,489,000 after buying an additional 95,353 shares in the last quarter.

About iShares U.S. Pharmaceuticals ETF

(Get Free Report)

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.